Payment overview · 2025
General Payments
$73.33
5 reported records · 3 companies
Healthcare provider profile · identity verified
Paul Daniel Silveri, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT, AR · NPI 1487917811
Verified facts
What the public records show
CMS Open Payments records show Paul Daniel Silveri, M.D. received $73.33 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 66.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.60 | 66.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.95 | 19.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.78 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $73.33 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.60 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $10.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 63 |
| Lisinopril | Lisinopril | 192 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 50 |
| Omeprazole | Omeprazole | 178 | 49 |
| Potassium Chloride | Potassium Chloride | 173 | 54 |
| Pregabalin | Pregabalin | 157 | 31 |
| Ozempic | Semaglutide | 153 | 31 |
| Alprazolam | Alprazolam | 147 | 33 |
| Gabapentin | Gabapentin | 133 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 42 |
| Metformin Hcl | Metformin Hcl | 130 | 44 |
| Furosemide | Furosemide | 128 | 39 |
| Eliquis | Apixaban | 120 | 26 |
| Losartan Potassium | Losartan Potassium | 114 | 37 |
| Carvedilol | Carvedilol | 104 | 26 |
| Sertraline Hcl | Sertraline Hcl | 104 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 21 |
| Famotidine | Famotidine | 81 | 27 |
| Ezetimibe | Ezetimibe | 78 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 27 |
| Meloxicam | Meloxicam | 77 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 17 |
| Jardiance | Empagliflozin | 73 | 13 |
| Tramadol Hcl | Tramadol Hcl | 72 | 25 |
| Clonazepam | Clonazepam | 70 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 19 |
| Trazodone Hcl | Trazodone Hcl | 65 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 17 |
| Prednisone | Prednisone | 59 | 33 |
| Cephalexin | Cephalexin | 58 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 12 |
| Cefuroxime | Cefuroxime Axetil | 51 | 40 |
| Allopurinol | Allopurinol | 50 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Azithromycin | Azithromycin | 46 | 35 |
| Torsemide | Torsemide | 45 | 11 |
| Simvastatin | Simvastatin | 40 | 14 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Promethazine Hcl | Promethazine Hcl | 36 | 12 |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Finasteride | Finasteride | 33 | 12 |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 15 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73.33 · 5 records | ABBVIE INC. | OTEZLA, REPATHA, Sunosi, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error